Compare · BDX vs SENS
BDX vs SENS
Side-by-side comparison of Becton Dickinson and Company (BDX) and Senseonics Holdings Inc. (SENS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and SENS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $43.58B, about 40.9x SENS ($1.07B).
- Over the past year, BDX is down 11.6% and SENS is down 55.9% - BDX leads by 44.3 points.
- BDX has been more active in the news (8 items in the past 4 weeks vs 4 for SENS).
- BDX has more recent analyst coverage (25 ratings vs 7 for SENS).
- Company
- Becton Dickinson and Company
- Senseonics Holdings Inc.
- Price
- $158.16-1.07%
- $5.13+0.00%
- Market cap
- $43.58B
- $1.07B
- 1M return
- +8.93%
- -29.24%
- 1Y return
- -11.60%
- -55.85%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- AMEX
- IPO
- News (4w)
- 8
- 4
- Recent ratings
- 25
- 7
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Senseonics Holdings Inc.
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to 90 and 180 days. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company was founded in 1996 and is headquartered in Germantown, Maryland.
Latest BDX
- BD to Announce Financial Results for its Third Quarter of Fiscal 2026
- EVP & President Connected Care Muhsin Bilal was granted 14,342 shares and covered exercise/tax liability with 1,935 shares, increasing direct ownership by 43% to 41,359 units (SEC Form 4) (for withholding tax)
- SEC Form 11-K filed by Becton Dickinson and Company
- SEC Form 11-K filed by Becton Dickinson and Company
- EVP, Chief Revenue Officer Feld Michael sold $11,460 worth of shares (75 units at $152.80) as part of a pre-agreed trading plan, decreasing direct ownership by 0.36% to 21,009 units (SEC Form 4)
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $160,226 worth of shares (1,100 units at $145.66) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 13,172 units (SEC Form 4)
- BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System
- New insider Sinha Manish claimed ownership of 8,806 shares (SEC Form 3)
- EVP & Pres Med.Essntl&BioPharm Garrison Michael David sold $166,628 worth of shares (1,100 units at $151.48) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 14,272 units (SEC Form 4)
- Chairman, CEO and President Polen Thomas E Jr exercised 20,209 shares at a strike of $126.16, returned $2,549,587 worth of shares to the company (17,445 units at $146.15) and sold $404,511 worth of shares (2,764 units at $146.35) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 110,163 units (SEC Form 4)
Latest SENS
- Director Fiorentino Edward was granted 2,635 shares, increasing direct ownership by 3% to 85,974 units (SEC Form 4)
- Director Prince Douglas S was granted 1,515 shares, increasing direct ownership by 2% to 69,331 units (SEC Form 4)
- Director Roeder Douglas A was granted 2,751 shares, increasing direct ownership by 2% to 157,238 units (SEC Form 4)
- Director Steven Edelman was granted 2,402 shares, increasing direct ownership by 3% to 91,083 units (SEC Form 4)
- Chief Medical Officer Kaufman Francine covered exercise/tax liability with 4,010 shares, decreasing direct ownership by 2% to 177,057 units (SEC Form 4) to cover taxes
- President and CEO Goodnow Timothy T covered exercise/tax liability with 32,598 shares, decreasing direct ownership by 3% to 1,143,748 units (SEC Form 4) (withholding obligation)
- GC & Corp. Development Advisor Horton Kenneth L covered exercise/tax liability with 9,545 shares, decreasing direct ownership by 3% to 285,512 units (SEC Form 4) to satisfy tax liability
- Chief Commercial Officer Hansen Brian B covered exercise/tax liability with 5,420 shares, decreasing direct ownership by 4% to 126,937 units (SEC Form 4) to satisfy tax liability
- Chief Operating Officer Jain Mukul covered exercise/tax liability with 16,194 shares, decreasing direct ownership by 3% to 500,863 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Sullivan Frederick T. covered exercise/tax liability with 5,397 shares, decreasing direct ownership by 2% to 226,477 units (SEC Form 4) to satisfy withholding obligation